Actinium Pharmaceuticals Inc (ATNM)

7.16 -0.32 (-4.28%) USD  |  NYAM  |  Jun 25, 16:00
7.17 +0.01 (+0.14%) After-Hours: 20:00
More

Actinium Pharmaceuticals Research and Development Expense (TTM): 37.46M for March 31, 2024

Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2012. Upgrade now.
Date Value
March 31, 2024 37.46M
December 31, 2023 38.67M
September 30, 2023 37.88M
June 30, 2023 33.03M
March 31, 2023 26.62M
December 31, 2022 23.14M
September 30, 2022 21.22M
June 30, 2022 19.16M
March 31, 2022 18.12M
December 31, 2021 18.03M
September 30, 2021 17.25M
June 30, 2021 16.33M
March 31, 2021 16.21M
December 31, 2020 16.09M
September 30, 2020 14.82M
June 30, 2020 15.86M
March 31, 2020 16.36M
December 31, 2019 16.55M
September 30, 2019 18.25M
June 30, 2019 17.64M
March 31, 2019 16.96M
December 31, 2018 17.09M
September 30, 2018 15.69M
Date Value
June 30, 2018 16.49M
March 31, 2018 17.61M
December 31, 2017 17.72M
September 30, 2017 18.28M
June 30, 2017 18.94M
March 31, 2017 18.64M
December 31, 2016 17.83M
September 30, 2016 16.39M
June 30, 2016 13.53M
March 31, 2016 13.22M
December 31, 2015 13.50M
September 30, 2015 15.12M
June 30, 2015 16.43M
March 31, 2015 14.73M
December 31, 2014 12.27M
September 30, 2014 8.598M
June 30, 2014 5.235M
March 31, 2014 3.613M
December 31, 2013 3.109M
September 30, 2013 3.090M
June 30, 2013 3.989M
March 31, 2013 4.081M
December 31, 2012 3.440M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

14.82M
Minimum
Sep 2020
38.67M
Maximum
Dec 2023
21.94M
Average
18.08M
Median

Research and Development Expense (TTM) Benchmarks

Perspective Therapeutics Inc 24.91M
Altimmune Inc 70.04M
Vertex Pharmaceuticals Inc 3.209B
SELLAS Life Sciences Group Inc 21.94M
Oragenics Inc 14.48M